MabionCD20 (candidate biosimilar to rituximab)

( DrugBank: - / KEGG DRUG: - )

1 disease

告示番号	疾患名（ページ内リンク）	臨床試験数
46	悪性関節リウマチ	1

46. 悪性関節リウマチ

臨床試験数 : 4,356 / 薬物数 : 2,567 - (DrugBank : 415) / 標的遺伝子数 : 192 - 標的パスウェイ数 : 228

trials per page:

Showing 1 to 1 of 1 trials

Filter by

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT04680962 (ClinicalTrials.gov)	October 17, 2021	2/12/2020	MabionCD20® Compared to MabThera® and Rituxan® in Patients With Rheumatoid Arthritis	A Double-Blind, Randomized, Parallel-Group Study toInvestigate the Pharmacokinetic and Clinical Simi ...	Rheumatoid Arthritis	Biological: MabionCD20 (candidate biosimilar to rituximab);Biological: MabThera®;Biological: Rituxan ...	Mabion SA	Parexel	Not yet recruiting	18 Years	80 Years	All	280	Phase 3	NULL

First Previous1Next Last